After Kura Oncology presented additional data on tipifarnib, a farnesyltransferase inhibitor/HRAS inhibitor that downregulates expression of CXCL12, Piper Jaffray analyst Tyler Van Buren said the number of potential indications for the drug “continues to multiply” as initial clinical data suggest diffuse large B-cell lymphoma and cutaneous T-cell lymphoma patients could benefit from treatment in addition to the already identified cancer indications. The “broad mechanism of tipifarnib is becoming clear” and the potential patient population keeps growing, “well beyond what investors are currently appreciating,” according to Van Buren. He keeps an Overweight rating on Kura shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.